<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201210165987N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-06-13</date_registration>
      <primary_sponsor>Vice chancellor for research, Faculty of Nursing and Midwifery, Tehran University of Medical Science</primary_sponsor>
      <public_title>The effect of decision aid in patients with breast cancer</public_title>
      <acronym></acronym>
      <scientific_title>The effect of decision aid package on selecting therapeutic option and decision outcomes among patients with early stage breast cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/6450</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Breast cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention 2: Intervention group at the first visit after confirm the diagnosis by physician, to get decision aid package were referred to the research nurse. Decision aid Package includes a information booklet and audiotape and personal worksheet. Information booklet contains information about the disease, treatment options, advantages and disadvantages of each treatment and the effect of treatment on patient survival and quality of life and were informed the patients for choose of one of therapeutic options (mastectomy or lumpectomy with radiation). The audiotape was twenty-minute long and supplements the booklet. And personal worksheet was in order to record the final decision and any questions, comments or ambiguity of the patients after study package. The patients were asked to return to their doctor up to four days later, after consultation with the people their trusted and study package, to discuss their questions and announce their final decision on the therapeutic option. Telephone follow-up during this period until the return of the patients to prevent the withdrawal of the samples was performed by a research nurse. On the second visit, treatment option and decision conflict questionnaire was completed. Eight weeks after beginning treatment decision regret questionnaire was completed. Patients telephone follow-up was done every two weeks during this eight weeks. Intervention 2: Intervention 2: The control group were received routine care. Decision aid package was not  given to this group. One to four days after the first visit (before beginning treatment) treatment option and decision conflict questionnaire was completed and eight weeks after treatment, decision regret questionnaire was completed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyyede Narjess Mousavizade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran, Tohid sq, Nosrat street, Faculty of nursing and midwifery, Tehran University of Medical Science</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6637 7579</telephone>
        <email>mousavi201089@yahoo.com</email>
        <affiliation>International Campus, Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Doctor Shahrzad Ghiyasvandiyan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran, Tohid sq, Faculty of nursing and midwifery,Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6642 0739</telephone>
        <email>shghiyas@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: all case studies will sign an informed consent, and also they should have the following conditions: 1) Have clinical stage 1 or 2 breast cancer that be approved by the physician 2) Not have previous history of cancer. 3) Not have serious non-malignant diseases such as cardiovascular, respiratory, renal, which may prevent definitive surgery . 4) They should be literate. 5) They should have language of Persian dialects. 6) Not have mental disorder and addictions which preventing decision-making process and giving informed consent for participating in this study. Exclusion criteria: In this study, if a patient has one of following characteristics, it will be excluded from the study: 1) If patient requires to intensive care. 2) If patient dies or migrate (so that access to the patient is not possible). 3) If patient participate in other studies</inclusion_criteria>
      <agemin>21 years</agemin>
      <agemax>78 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention 2: Intervention group at the first visit after confirm the diagnosis by physician, to get decision aid package were referred to the research nurse. Decision aid Package includes a information booklet and audiotape and personal worksheet. Information booklet contains information about the disease, treatment options, advantages and disadvantages of each treatment and the effect of treatment on patient survival and quality of life and were informed the patients for choose of one of therapeutic options (mastectomy or lumpectomy with radiation). The audiotape was twenty-minute long and supplements the booklet. And personal worksheet was in order to record the final decision and any questions, comments or ambiguity of the patients after study package. The patients were asked to return to their doctor up to four days later, after consultation with the people their trusted and study package, to discuss their questions and announce their final decision on the therapeutic option. Telephone follow-up during this period until the return of the patients to prevent the withdrawal of the samples was performed by a research nurse. On the second visit, treatment option and decision conflict questionnaire was completed. Eight weeks after beginning treatment decision regret questionnaire was completed. Patients telephone follow-up was done every two weeks during this eight weeks.</i_keyword>
      <i_keyword>Intervention 2: The control group were received routine care. Decision aid package was not  given to this group. One to four days after the first visit (before beginning treatment) treatment option and decision conflict questionnaire was completed and eight weeks after treatment, decision regret questionnaire was completed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Select therapeutic option. Timepoint: One to four days after intervention. Method of measurement: O'Connor questionnaire.</prim_outcome>
      <prim_outcome>ِِDecision conflict. Timepoint: 1-4 days after intervention. Method of measurement: O'Connor traditional decisional conflict scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Decision Regret. Timepoint: Eight weeks after intervention. Method of measurement: O'Connor Decision  Regret  Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Faculty of Nursing and Midwifery, Tehran University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-09-30</approval_date>
        <contact_name>Tehran University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Tehran, Keshavarz blvd, Ghods st. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
